Alemtuzumab / LEMTRADA ELISA
Alemtuzumab / LEMTRADA is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma. It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and Islet cell transplantation. Alemtuzumab binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. It was approved by the US Food and Drug Administration for CLL patients who have been treated with alkylating agents and who have failed fludarabine therapy. It has been approved by Health Canada for the same indication, and additionally for CLL patients who have not had any previous therapies.
Intended Use: This Alemtuzumab / LEMTRADA ELISA is a rapid and easy method for the quantitative determination of Alemtuzumab in human serum, plasma and cell culture supernatant. The Alemtuzumab is for research use only. Not for diagnostic or therapeutic procedures.
Principle: The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Alemtuzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Alemtuzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti- Alemtuzumab antibody is pipetted and incubated with samples. After washing microwells in order to remove any non specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Alemtuzumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
The kit uses a sandwich ELISA format to quantify the target cytokine between two layers of antibodies (i.e. capture and detection antibody). The cytokine to be measured contains at least two antigenic epitope capable of binding to antibody, since at least two antibodies act in the sandwich. The advantage of Sandwich ELISA is that the sample does not have to be purified before analysis, and the assay can be very sensitive upto pg/ml levels (more sensitive than direct or indirect ELISA). A highly efficient blocking and stabilizing proprietary solution is used in the kit. All KRISHGEN cytokine ELISA kits are optimized to give the best possible noise:signal ratios.
KRISHGEN BIOSYSTEMS is a leading manufacturer of immunoassay kits including ELISA. KRISHGEN has over 200 publications and citations to its credit which speaks of its quality and accuracy. Leaders in many areas of research, ELISAs manufactured by KRISHGEN are used for quality research and reproducibility at competitive prices. Diverse product range includes ELISA for diagnostics, cytokines, biopharmaceuticals, HCP, downstream contamination, PK studies for Mabs, immunogenicity, vaccine, animal health testing, plant pathology, GMO and food safety.
ELISA 96 wells
Publishing research using this product? Please let us know so that we can cite the reference for this product.